Natera, Inc. logo NTRA - Natera, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 25
HOLD 2
SELL 0
STRONG
SELL 0
| PRICE TARGET: $261.75 DETAILS
HIGH: $285.00
LOW: $220.00
MEDIAN: $267.50
CONSENSUS: $261.75
UPSIDE: 28.82%

Stock News

Natera to Present 35 Studies at ASCO, Extending Clinical Data Leadership in Oncology

Natera to Present 35 Studies at ASCO, Extending Clinical Data Leadership in Oncology

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a landmark oncology data program for the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting will take place May 29–June 2 in Chicago, IL. Together with its collaborators, Natera will demonstrate unmatched scale in evidence generation with 35 abstracts across molecular residual disease (MRD) testing and other innovations. Presentations w.

May 21, 2026 01:05 PM • businesswire.com
Natera Announces Expansion in Austin, Creating What Is Believed to Be the Largest Sequencing Facility in the World

Natera Announces Expansion in Austin, Creating What Is Believed to Be the Largest Sequencing Facility in the World

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a significant expansion of its operations, marking a major milestone in the company's continued growth and mission to improve outcomes for patients with cancer and other serious diseases. At its North Austin headquarters campus, Natera will unveil two major expansion projects: a dedicated sequencing facility, significantly increasing capacity; and an additional s.

May 21, 2026 03:00 AM • businesswire.com
EXPAND Trial of Natera's Fetal Focus™ Single-Gene NIPT Surpasses >2,000 Patients Enrolled

EXPAND Trial of Natera's Fetal Focus™ Single-Gene NIPT Surpasses >2,000 Patients Enrolled

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced that the EXPAND clinical trial has enrolled over 2,000 patients, more than doubling enrollment in the last 12 months. EXPAND is a prospective, blinded, multi-site clinical trial designed to study Natera's Fetal Focus single-gene noninvasive prenatal test (NIPT). The trial was featured in an oral plenary session at the Society for Maternal-Fetal Me.

May 20, 2026 03:00 AM • businesswire.com
Signatera™ CDx Approved by the FDA as a Companion Diagnostic in Muscle-Invasive Bladder Cancer (MIBC)

Signatera™ CDx Approved by the FDA as a Companion Diagnostic in Muscle-Invasive Bladder Cancer (MIBC)

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved Signatera CDx as a companion diagnostic (CDx) for use with adjuvant atezolizumab (Tecentriq®) immunotherapy in MIBC. This is the first companion diagnostic approval in the field of blood-based MRD. It is a significant milestone in the industry-wide shift toward personalized, MRD-guided cancer care, in.

May 15, 2026 08:45 AM • businesswire.com
AI, Obesity Drugs, and Diagnostics Fuel Healthcare Growth

AI, Obesity Drugs, and Diagnostics Fuel Healthcare Growth

Healthcare is regaining momentum as innovation—especially AI‑driven drug discovery—creates new growth opportunities, according to Shivani Vohra. She points to obesity treatments from Eli Lilly (LLY) and Novo Nordisk (NVO), advances in diagnostics from Natera (NTRA), and continued strength in med tech leaders like Intuitive Surgical (ISRG) and Edwards Lifesciences (EW) as key areas of expansion.

May 10, 2026 10:30 AM • youtube.com
Natera Q1 Earnings Call Highlights

Natera Q1 Earnings Call Highlights

Natera NASDAQ: NTRA reported first-quarter 2026 revenue of $697 million, up 39% year over year, as the company delivered more than 1 million total units in a single quarter for the first time. Chief Executive Officer Steve Chapman said strong performance in women's health and another record quarter in oncology drove the results, while Chief Financial Officer Michael Brophy highlighted continued improvement in realized pricing and reimbursement dynamics.

May 08, 2026 12:08 PM • marketbeat.com
Natera Reports First Quarter 2026 Financial Results

Natera Reports First Quarter 2026 Financial Results

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the first quarter ended March 31, 2026. Recent Financial Highlights Generated total revenues of $696.6 million in the first quarter of 2026, compared to $501.8 million in the first quarter of 2025, an increase of 38.8%. Generated a gross margin1 of 64.7% in the first quarter of 2026, compared to a gross margin1 of 63.1% in the first quarter.

May 07, 2026 12:05 PM • businesswire.com
Prospera™ Evidence in Heart and Lung Transplantation Featured Across 17 Presentations at ISHLT

Prospera™ Evidence in Heart and Lung Transplantation Featured Across 17 Presentations at ISHLT

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a broad body of evidence supporting its Prospera test at the 2026 International Society for Heart and Lung Transplantation (ISHLT) Annual Meeting. Prospera will be featured in 17 abstracts, including six oral presentations. Together with academic colleagues, Natera will highlight Prospera's expanding clinical utility in heart and lung transplantation, spanning re.

Apr 22, 2026 05:00 AM • businesswire.com
Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics' MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma

Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics' MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today highlighted Allogene Therapeutics' (NASDAQ: ALLO) interim futility analysis from its registrational ALPHA3 trial for cemacabtagene ansegedleucel (cema-cel), an investigational allogeneic anti-CD19 CAR T therapy, in first-line (1L) consolidation large B-cell lymphoma (LBCL). The ALPHA3 trial is enrolling patients with LBCL who test positive for molecular residual disease (M.

Apr 13, 2026 04:00 AM • businesswire.com
Judge Awards 30% Ongoing Royalty to Natera for its MRD-Related Patents

Judge Awards 30% Ongoing Royalty to Natera for its MRD-Related Patents

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today provided an update on a recent decision issued by the United States District Court in the District of Delaware regarding Natera's litigation with ArcherDx and Invitae. In a decision issued on April 6, 2026, the Court ordered an ongoing royalty to Natera of 30% on post-injunction revenues from infringing MRD-related product sales that fall within the exceptions to the injun.

Apr 09, 2026 02:00 AM • businesswire.com

Price Targets